PRINCETON, N.J., July 08, 2024--Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day
Bristol Myers Squibb has agreed to pay 10 million shekels ($2.7 million) in Israel to settle a potential case over its blocking of a generic version for anti-cancer drug Imnovid, Israel's Competition Authority said on Monday. The anti-trust agency said that Bristol and Neopharm Scientific, the Israeli distributor of Imnovid - used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma - declined a request by KS Kim International for drug samples to make a copycat version of Imnovid.
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.